Sökning: "allogeneic stem cell transplantation"
Visar resultat 1 - 5 av 97 avhandlingar innehållade orden allogeneic stem cell transplantation.
1. Allogeneic stem cell transplantation : patients’ and sibling donors’ perspectives
Sammanfattning : Allogeneic haematopoietic stem cell transplantation (hereafter HSCT) is an established treatment which offers a potential cure for a variety of diseases, mainly haematological malignancies. However, the treatment is also associated with significant risks of acute complications and late side effects, including mortality. LÄS MER
2. Potential Hazards for Haematopoietic Stem Cell Donors
Sammanfattning : The aim of this thesis has been to increase our knowledge about the allogeneic stem cell donation procedure and the associated risks for stem cell donors. In a first study (paper I), we described the donation procedure and short-term side effects of 1957 donors included in the Nordic Register of Haematopoietic Stem Cell Donors. LÄS MER
3. Life situation in patients and their family members after allogeneic hematopoietic stem cell transplantation : aspects of health and support in different care settings
Sammanfattning : Allogeneic hematopoietic stem cell transplantation (HSCT) is mainly an intensive treatment option for hematology malignancies. During the past decades, improved care and treatment have been systematically developed. LÄS MER
4. Alloreactivity in stem cell transplantation
Sammanfattning : Acute graft-versus-host disease (GVHD), relapse and graft rejection are the main complications after allogeneic hematopoietic stem cell transplantation (HSCT). The aim of this thesis was to achieve a better understanding of the alloreactivity seen after HSCT, focusing on graft rejection, but also including the graft-versus-leukemia (GVL) effect and GVHD. LÄS MER
5. Immune reconstitution after allogeneic hematopoietic stem cell transplantation
Sammanfattning : After treatment with allogeneic hernatopoietic stem cell transplantation (HSCT) the patient suffers from a deficient immune system for at least 12 months or longer. During this period, the patient is susceptible to infections and if the state of immune deficiency is prolonged there is an increased risk of relapse of the underlying malignancy as well as development of secondary malignancies. LÄS MER